|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation, endothelial glycocalyx, and clinical course
Description: PPV describes microcirculation dysfunctionMeasure: change in Proportion of Perfused Vessels (PPV) parameter Time: 1st, 2nd and 3rd day
Description: Syndecan-1 is a marker of endothelial glycocalyxMeasure: change in Syndecan-1 serum concentration Time: 1st, 2nd and 3rd day
Description: albuminuria is a marker of glomerular endothelial cells dysfunctionMeasure: change in albuminuria Time: 1st, 2nd and 3rd day
Description: mortality in 28 days from ICU admissionMeasure: mortality in 28 days Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports